July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
The FDA approval provides physicians with a once-daily oral PCSK9 inhibitor option to reduce LDL-C in adults with high cholesterol, including those with heterozygous familial hypercholesterolemia.
New guideline recommendations from the ACC/AHA and 9 partner organizations prioritize earlier treatment, refined atherosclerotic cardiovascular disease risk prediction, and broader use of lipid biomarkers...
A randomized clinical trial found that a nurse-led intervention strategy could improve systolic blood pressure and non-high-density lipoprotein cholesterol in patients with HIV, reducing their risk of...
Among those with statin-intolerance, bempedoic acid, an inhibitor used to decrease elevated levels of low-density lipoprotein cholesterol, was also associated with a lower risk of major adverse...
The researchers observed trends in cardiovascular disease risk profiles across various populations to better understand the impact of secondary prevention resources.
In a recent study, researchers examined whether consuming food with more functional bioactives can effectively lower cholesterol in adults with hyperlipidemia.
The FDA has approved a new agent for lowering LDL-C in adults with heterozygous familial hypercholesterolemia or established ASCVD as an adjunct to diet and maximally tolerated statin therapy.
In a recent study, researchers examined the association between non-HDL cholesterol and the long-term risk of cardiovascular disease, and how reducing cholesterol concentrations affected this risk.
It is unclear whether higher thresholds of non-high-density lipoprotein cholesterol are more strongly associated with metabolic syndrome in adolescents and young adults with obesity. Therefore, authors of a...
